<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082586</url>
  </required_header>
  <id_info>
    <org_study_id>SGH201705</org_study_id>
    <nct_id>NCT03082586</nct_id>
  </id_info>
  <brief_title>Radiation Dose Escalation in Esophageal Cancer</brief_title>
  <official_title>Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to find the maximum tolerable dose of radiation that can be
      delivered combined with chemotherapy (DDP &amp; Paclitaxel) in patients with inoperable or
      medically unresectable esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RTOG 8501 has established concurrent radiochemotherapy as the standard of care for cancer
      of the esophagus.However, locoregional remain problematic, with 25% of patients having
      persistence and 20% relapse of locoregional disease following the combined modality approach.
      New regimen is urgently needed for improving localregional control and survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2016</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (DLTs) Occurring in Participants</measure>
    <time_frame>15 months</time_frame>
    <description>The DLTs were defined as grade &gt;/=4 esophatitis, any other grade &gt;/=3 nonhematological toxicity (except nausea and vomiting), or grade &gt;/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Local Failure</measure>
    <time_frame>15 months</time_frame>
    <description>Local control will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 57.2 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 64.4 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 71.6 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 78.8 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 86 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with radiation therapy 93.2 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 1</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 1</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 2</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 2</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 3</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 3</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 4</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 4</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 5</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
    <arm_group_label>radiochemotherapy 5</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiochemotherapy 6</intervention_name>
    <description>concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
    <arm_group_label>radiochemotherapy 6</arm_group_label>
    <other_name>concurrent chemoradiotherapy regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed primary squamous cell carcinoma of the esophagus

          2. Age 1 8-75.

          3. Patients must be deemed unresectable disease or patient is not deemed operable due to
             medical reasons.

          4. Patients with distant metastasis and life expectancy &gt;/= 3 months are eligible.

          5. Zubrod performance status 0 to 2

          6. No prior radiation to the thorax that would overlap with the current treatment field.

          7. Patients with nodal involvement are eligible

          8. Adequate bone marrow, renal and hepatic functions as assessed by the following:
             Hemoglobin &gt;/= 10.0 g/dl, Platelet count &gt;/= 1 00,000/mm^3,absolute granulocyte count
             (AGC) ≥2 × 10^9 cells/L,bilirubin and Aspartate transaminase ≤1.5 ×upper limit of
             normal (ULN), Creatinine &lt;/=1 .5 times ULN.

          9. A signed informed consent must be obtained prior to therapy. 1 0. Induction
             chemotherapy is allowed.

        Exclusion Criteria:

          1. The presence of a fistula.

          2. Prior radiotherapy that would overlap the radiation fields.

          3. gastroesophageal junction cancer.

          4. Uncontrolled concurrent illness including, but not limited to: Chronic Obstructive
             Pulmonary Disease(COPD) exacerbation or other respiratory illness, serious
             uncontrolled infection, symptomatic congestive heart failure (CHF),unstable angina
             pectoris, uncontrolled hypertension,or psychiatric illness/social situations that
             would limit compliance with the study requirements.

          5. Known hypersensitivity to paclitaxel.

          6. Any other condition or circumstance that would, in the opinion of the Investigator,
             make the patient unsuitable for participation in the study.

          7. Acquired Immune Deficiency Syndrome.

          8. Conditions precluding medical follow-up and protocol compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tingfeng Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the ethic committee of shanghai genernal hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Ethic Committee of Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999 May 5;281(17):1623-7.</citation>
    <PMID>10235156</PMID>
  </reference>
  <reference>
    <citation>Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992 Jun 11;326(24):1593-8.</citation>
    <PMID>1584260</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <results_first_submitted>March 28, 2020</results_first_submitted>
  <results_first_submitted_qc>June 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2020</results_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chen tingfeng</investigator_full_name>
    <investigator_title>Director,department of radiation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03082586/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiochemotherapy 1</title>
          <description>Patients will be treated with radiation therapy 57.2 Gy.
radiochemotherapy 1: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="P2">
          <title>Radiochemotherapy 2</title>
          <description>Patients will be treated with radiation therapy 64.4 Gy.
radiochemotherapy 2: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="P3">
          <title>Radiochemotherapy 3</title>
          <description>Patients will be treated with radiation therapy 71.6 Gy.
radiochemotherapy 3: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="P4">
          <title>Radiochemotherapy 4</title>
          <description>Patients will be treated with radiation therapy 78.8 Gy.
radiochemotherapy 4: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="P5">
          <title>Radiochemotherapy 5</title>
          <description>Patients will be treated with radiation therapy 86 Gy.
radiochemotherapy 5: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
        </group>
        <group group_id="P6">
          <title>Radiochemotherapy 6</title>
          <description>Patients will be treated with radiation therapy 93.2 Gy.
radiochemotherapy 6: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">the patients received a total radiation dose of 57.2 Gy in this group</participants>
                <participants group_id="P2" count="3">the patients received a total radiation dose of 64.4 Gy in this group</participants>
                <participants group_id="P3" count="3">the patients received a total radiation dose of 71.6 Gy in this group</participants>
                <participants group_id="P4" count="6">the patients received a total radiation dose of 78.8 Gy in this group</participants>
                <participants group_id="P5" count="13">the patients received a total radiation dose of 86 Gy in this group</participants>
                <participants group_id="P6" count="3">the patients received a total radiation dose of 93.2 Gy in this group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">the patients received a total radiation dose of 57.2 Gy in this group</participants>
                <participants group_id="P2" count="3">the patients received a total radiation dose of 64.4 Gy in this group</participants>
                <participants group_id="P3" count="3">the patients received a total radiation dose of 71.6 Gy in this group</participants>
                <participants group_id="P4" count="6">the patients received a total radiation dose of 78.8 Gy in this group</participants>
                <participants group_id="P5" count="13">the patients received a total radiation dose of 86 Gy in this group</participants>
                <participants group_id="P6" count="3">the patients received a total radiation dose of 93.2 Gy in this group</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiochemotherapy 1</title>
          <description>3 Patients will be treated with radiation therapy 57.2 Gy.
radiochemotherapy 1: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="B2">
          <title>Radiochemotherapy 2</title>
          <description>3 Patients will be treated with radiation therapy 64.4 Gy.
radiochemotherapy 2: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="B3">
          <title>Radiochemotherapy 3</title>
          <description>3 Patients will be treated with radiation therapy 71.6 Gy.
radiochemotherapy 3: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="B4">
          <title>Radiochemotherapy 4</title>
          <description>6 Patients will be treated with radiation therapy 78.8 Gy.
radiochemotherapy 4: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="B5">
          <title>Radiochemotherapy 5</title>
          <description>13 Patients will be treated with radiation therapy 86 Gy.
radiochemotherapy 5: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
        </group>
        <group group_id="B6">
          <title>Radiochemotherapy 6</title>
          <description>3 Patients will be treated with radiation therapy 93.2 Gy.
radiochemotherapy 6: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="3"/>
                    <count group_id="B7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="3"/>
                    <count group_id="B7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="3"/>
                    <count group_id="B7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group, ECOG performance status 0-1</title>
          <description>GRADE ECOG PERFORMANCE STATUS
0 Fully active, able to carry on all pre-disease performance without restriction
Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
Completely disabled; cannot carry on any selfcare; totally confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="3"/>
                    <count group_id="B4" value="6"/>
                    <count group_id="B5" value="13"/>
                    <count group_id="B6" value="3"/>
                    <count group_id="B7" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicities (DLTs) Occurring in Participants</title>
        <description>The DLTs were defined as grade &gt;/=4 esophatitis, any other grade &gt;/=3 nonhematological toxicity (except nausea and vomiting), or grade &gt;/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment.</description>
        <time_frame>15 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Radiochemotherapy 1</title>
            <description>Patients will be treated with radiation therapy 57.2 Gy.
radiochemotherapy 1: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Radiochemotherapy 2</title>
            <description>Patients will be treated with radiation therapy 64.4 Gy.
radiochemotherapy 2: concurrent radiochemotherapy: radiotherapy dose level 2: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
          <group group_id="O3">
            <title>Arm 3：Radiochemotherapy 3</title>
            <description>Patients will be treated with radiation therapy 71.6 Gy.
radiochemotherapy 3: concurrent radiochemotherapy: radiotherapy dose level 3: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: Radiochemotherapy 4</title>
            <description>Patients will be treated with radiation therapy 78.8 Gy.
radiochemotherapy 4: concurrent radiochemotherapy: radiotherapy dose level 4: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: Radiochemotherapy 5</title>
            <description>Patients will be treated with radiation therapy 86 Gy.
radiochemotherapy 5: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
          <group group_id="O6">
            <title>Arm 6: Radiochemotherapy 6</title>
            <description>Patients will be treated with radiation therapy 93.2 Gy.
radiochemotherapy 6: concurrent radiochemotherapy: radiotherapy dose level 6: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicities (DLTs) Occurring in Participants</title>
          <description>The DLTs were defined as grade &gt;/=4 esophatitis, any other grade &gt;/=3 nonhematological toxicity (except nausea and vomiting), or grade &gt;/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment.</description>
          <units>dose limiting toxicity</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Local Failure</title>
        <description>Local control will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan.</description>
        <time_frame>15 months</time_frame>
        <posting_date>06/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Radiochemotherapy 1</title>
          <description>Patients will be treated with radiation therapy 57.2 Gy.
radiochemotherapy 1: concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 57.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: Radiochemotherapy 2</title>
          <description>Patients will be treated with radiation therapy 64.4 Gy.
radiochemotherapy 2: concurrent radiochemotherapy: radiotherapy dose level 2: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Radiochemotherapy 3</title>
          <description>Patients will be treated with radiation therapy 71.6 Gy.
radiochemotherapy 3: concurrent radiochemotherapy: radiotherapy dose level 3: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: Radiochemotherapy 4</title>
          <description>Patients will be treated with radiation therapy 78.8Gy.
radiochemotherapy 4: concurrent radiochemotherapy: radiotherapy dose level 4: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="E5">
          <title>Arm 5: Radiochemotherapy</title>
          <description>Patients will be treated with radiation therapy 36 Gy.
radiochemotherapy 5: concurrent radiochemotherapy: radiotherapy dose level 5: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
        <group group_id="E6">
          <title>Arm 6: Radiochemotherapy 6</title>
          <description>Patients will be treated with radiation therapy 93.2 Gy.
radiochemotherapy 6: concurrent radiochemotherapy: radiotherapy dose level 6: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>grade 5 esophageal fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>grade 3 pneumotitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" events="11" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr tingfeng Chen</name_or_title>
      <organization>Department of Radiation Oncology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</organization>
      <phone>86-021-37798364</phone>
      <email>tingfeng138138@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

